Based on the Applied Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Applied Therapeutics Inc is USD 10.50 over the next 12 months. Applied Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Applied Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Applied Therapeutics Inc’s stock price was USD 9.63. Applied Therapeutics Inc’s stock price has changed by +10.76% over the past week, +7.30% over the past month and +406.58% over the last year.
No recent analyst target price found for Applied Therapeutics Inc
No recent average analyst rating found for Applied Therapeutics Inc
Company Overview Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017 Read Less
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is...Read More
Frequently Asked Questions About Applied Therapeutics Inc (APLT) Stock
Based on ratings from 3 analysts Applied Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on APLT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for APLT is USD 10.50 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on APLT's stock to indicate if its overvalued.
The last closing price of APLT's stock was USD 9.63.
The most recent market capitalization for APLT is USD 1.12B.
Based on targets from 3 analysts, the average taret price for APLT is projected at USD 10.50 over the next 12 months.
This means that APLT's stock price may go up by +9.09% over the next 12 months.
We can't find any ETFs which contains Applied Therapeutics Inc's stock.
As per our most recent records Applied Therapeutics Inc has 37 Employees.
Applied Therapeutics Inc's registered address is 545 Fifth Avenue, New York, NY, United States, 10017.
You can get more information about it from Applied Therapeutics Inc's website at https://www.appliedtherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Applied Therapeutics Inc (APLT) Stock
Based on ratings from 3 analysts Applied Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on APLT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for APLT is USD 10.50 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on APLT's stock to indicate if its overvalued.
The last closing price of APLT's stock was USD 9.63.
The most recent market capitalization for APLT is USD 1.12B.
Based on targets from 3 analysts, the average taret price for APLT is projected at USD 10.50 over the next 12 months.
This means that APLT's stock price may go up by +9.09% over the next 12 months.
We can't find any ETFs which contains Applied Therapeutics Inc's stock.
As per our most recent records Applied Therapeutics Inc has 37 Employees.
Applied Therapeutics Inc's registered address is 545 Fifth Avenue, New York, NY, United States, 10017.
You can get more information about it from Applied Therapeutics Inc's website at https://www.appliedtherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APLT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
